CD33 Chimeric Monoclonal Antibody

<strong>CD33 Chimeric Monoclonal Antibody</strong>_x000D_ <strong>Catalog number:</strong> B2017705_x000D_ <strong>Lot number:</strong> Batch Dependent_x000D_ <strong>Expiration Date:</strong> Batch dependent_x000D_ <strong>Amount:</strong> 100 µg_x000D_ <strong>Molecular Weight or Concentration:</strong> N/A_x000D_ <strong>Supplied as:</strong> Solution_x000D_ <strong>Applications:</strong> a molecular tool for various biochemical applications_x000D_ <strong>Storage:</strong> -20°C_x000D_ <strong>Keywords:</strong> Cluster of Differentiation 33, Myeloid Cell Surface Antigen CD33, Sialic Acid-binding Ig-like Lectin 3, Siglec-3_x000D_ <strong>Grade:</strong> Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity &gt;18 MΩ-cm) and are filtered through 0.22 um._x000D_ _x000D_ <strong>References:</strong>_x000D_ 1: Liu Y, Wang S, Schubert ML, Lauk A, Yao H, Blank MF, Cui C, Janssen M, Schmidt C, Göllner S, Kleist C, Zhou F, Rahfeld JU, Sauer T, Schmitt M, Müller-Tidow C. CD33-directed immunotherapy with third-generation chimeric antigen receptor T cells and gemtuzumab ozogamicin in intact and CD33-edited acute myeloid leukemia and hematopoietic stem and progenitor cells Int J Cancer. 2022 Apr 1;150(7):1141-1155._x000D_ 2: Jacobs SA, Foon KA. Monoclonal antibody therapy of leukaemias and lymphomas Expert Opin Biol Ther. 2005 Sep;5(9):1225-43._x000D_ 3: Masarova L, Kantarjian H, Garcia-Mannero G, Ravandi F, Sharma P, Daver N. Harnessing the Immune System Against Leukemia: Monoclonal Antibodies and Checkpoint Strategies for AML Adv Exp Med Biol. 2017;995:73-95._x000D_ 4: Maakaron JE, Rogosheske J, Long M, Bachanova V, Mims AS. CD33-Targeted Therapies: Beating the Disease or Beaten to Death? J Clin Pharmacol. 2021 Jan;61(1):7-17._x000D_ 5: Godwin CD, Laszlo GS, Fiorenza S, Garling EE, Phi TD, Bates OM, Correnti CE, Hoffstrom BG, Lunn MC, Humbert O, Kiem HP, Turtle CJ, Walter RB. Targeting the membrane-proximal C2-set domain of CD33 for improved CD33-directed immunotherapy Leukemia. 2021 Sep;35(9):2496-2507._x000D_ 6: Rashidi A, Walter RB. Antigen-specific immunotherapy for acute myeloid leukemia: where are we now, and where do we go from here? Expert Rev Hematol. 2016;9(4):335-50._x000D_ 7: Patel SA, Bello E, Wilks A, Gerber JM, Sadagopan N, Cerny J. Harnessing autologous immune effector mechanisms in acute myeloid leukemia: 2023 update of trials and tribulations Leuk Res. 2023 Nov;134:107388._x000D_ 8: Laszlo GS, Estey EH, Walter RB. The past and future of CD33 as therapeutic target in acute myeloid leukemia Blood Rev. 2014 Jul;28(4):143-53._x000D_ 9: Buckley SA, Walter RB. Update on antigen-specific immunotherapy of acute myeloid leukemia Curr Hematol Malig Rep. 2015 Jun;10(2):65-75._x000D_ <a href="https://pubmed.ncbi.nlm.nih.gov/20035683">10: Cartron G, Rossi JF. [Therapeutic monoclonal antibodies in onco-hematology] Med Sci (Paris). 2009 Dec;25(12):1085-9. </a>_x000D_ _x000D_ <strong>Products Related to CD33 Chimeric Monoclonal Antibody can be found at</strong> <a href="https://moleculardepot.com/product-category/Antibodies/"> Antibodies</a>